Travel and Leisure Travel and Leisure

Zepbound Helps People Shed More Weight Than Wegovy, According to Eli Lilly Trial


Published on 2024-12-14 17:23:16 - MSN
  Print publication without navigation

  • Fact checked by Nick Blackmer Eli Lilly's Zepbound bested Novo Nordisk's Wegovy in the first head-to-head trial comparing weight loss outcomes for people with obesity or overweight, according to top-line results shared by Lilly last week.

The article from MSN discusses a clinical trial conducted by Eli Lilly, which found that their new weight-loss drug, Zepbound (tirzepatide), helped participants lose more weight than those using Wegovy (semaglutide), a similar drug by Novo Nordisk. In the trial, participants on Zepbound lost up to 26.6% of their body weight over 84 weeks, compared to Wegovy users who lost about 15.8%. Zepbound works by mimicking the effects of two gut hormones, GLP-1 and GIP, which help regulate appetite and blood sugar. The trial results suggest that Zepbound could offer a more effective option for weight management, although it also comes with side effects like nausea and diarrhea, similar to other drugs in its class. The findings are significant as they could influence future treatments for obesity, a condition linked to numerous health issues.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/health/weightloss/zepbound-helps-people-shed-more-weight-than-wegovy-according-to-eli-lilly-trial/ar-AA1vS3N2 ]